Company Description
Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of proprietary life support technology for the treatment of acute respiratory failure.
Its lead product is the INSPIRA augmented respiration technology (Gen 2) device, a life support designed to provide Adaptive Blood Oxygenation that to elevate and stabilize declining oxygen saturation levels.
The company has a strategic collaboration with Westchester Medical Center to advance critical patient care with the deployment of Inspira's proprietary INSPIRA ART100 systems.
The company was formerly known as Insense Medical Ltd. and changed its name to Inspira Technologies Oxy B.H.N.
Ltd. in July 2020. Inspira Technologies Oxy B.H.N.
Ltd. was incorporated in 2018 and is headquartered in Ra'anana, Israel.
| Country | Israel |
| Founded | 2018 |
| IPO Date | Jul 14, 2021 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 42 |
| CEO | Dagi Ben-Noon |
Contact Details
Address: 2 Ha-Tidhar Street Ra'anana, 4366504 Israel | |
| Phone | 972 4 6230333 |
| Website | inspira-technologies.com |
Stock Details
| Ticker Symbol | IINN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.51 |
| CIK Code | 0001837493 |
| CUSIP Number | M53637100 |
| ISIN Number | IL0011715781 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Dagi Shahar Ben-Noon | Co-Founder, Chief Executive Officer and Director |
| Joe Hayon | Co-Founder, President and Director |
| Yafit Tehila | Chief Financial Officer |
| Avi Shabtai | Chief Operating Officer and Vice President of Research and Development |
| Daniella Yeheskely-Hayon Ph.D. | Chief Technology Officer |
| Meshira Greenberg | Administrative Manager |
| Adi Shmueli | Director of Marketing |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 11, 2025 | 6-K | Report of foreign issuer |
| Mar 10, 2025 | 20-F | Annual and transition report of foreign private issuers |
| Mar 5, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 4, 2025 | 6-K | Report of foreign issuer |
| Feb 11, 2025 | 6-K | Report of foreign issuer |
| Feb 10, 2025 | 6-K | Report of foreign issuer |
| Feb 5, 2025 | 6-K | Report of foreign issuer |
| Jan 30, 2025 | 424B4 | Prospectus |
| Jan 27, 2025 | 6-K | Report of foreign issuer |
| Jan 23, 2025 | EFFECT | Notice of Effectiveness |